Ondine Biomedical Secures First UK NHS Deal for Antimicrobial Technology
TL;DR
Ondine Biomedical Inc sealed its first commercial deal with an NHS trust, gaining an early advantage in the healthcare market.
The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics, leading to broader NHS adoption and deployment in healthcare facilities.
Ondine Biomedical's Steriwave is making the world a better place by improving healthcare outcomes, reducing antibiotic use, and contributing to antimicrobial resistance efforts.
Ondine Biomedical Inc is expanding its international presence in Canada, UK, and Spain, while also exploring potential in the United States through FDA phase three trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Ondine Biomedical Inc. has achieved a significant milestone with its first commercial agreement in the United Kingdom's National Health Service system. The Canadian antimicrobial photodisinfection specialist has secured adoption of its Steriwave technology by Pontefract and Pinderfields hospitals following a successful 500-patient elective hip and knee surgical quality initiative at Pontefract. This development marks a crucial step in the company's international expansion and represents growing recognition of photodisinfection technology's potential in healthcare settings.
Matt Ross, Vice President of Sales & Marketing at Ondine Biomedical, expressed enthusiasm about this breakthrough achievement. The company's successful demonstration of positive outcomes and favorable health economics has paved the way for this commercial adoption. Ondine now plans to develop a comprehensive business case with the York health economics group and Mid Yorkshire to support broader NHS implementation across the United Kingdom. This strategic approach leverages the compelling results from the initial trial period and positions the technology for wider healthcare system integration.
The UK adoption forms part of Ondine's expanding commercial momentum globally. The Steriwave technology is currently deployed across eight new healthcare facilities, bringing the total to 22 facilities in Canada while simultaneously expanding its presence in both the United Kingdom and Spain. This growth trajectory underscores the increasing acceptance of photodisinfection as a viable infection control method. The technology's effectiveness in reducing antibiotic usage, as demonstrated in a UK study available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903725/, aligns perfectly with global efforts to combat antimicrobial resistance, making it particularly relevant in current healthcare landscapes.
Looking ahead, Ondine Biomedical plans to continue its European market expansion while capitalizing on established success in Canada. The company is also exploring potential market entry in the United States through ongoing FDA phase three trials. Ondine's innovative approach to antimicrobial photodisinfection positions the technology as a promising solution in the global fight against antibiotic resistance and healthcare-associated infections. As healthcare systems worldwide grapple with the challenges of antimicrobial resistance, technologies like Steriwave offer potential alternatives to traditional antibiotic-based approaches, potentially transforming infection control protocols in surgical and clinical environments.
Curated from News Direct
